Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Purchased by Trexquant Investment LP

Key Points

• Trexquant Investment LP significantly increased its stake in Structure Therapeutics by 127.6% during the 1st quarter, owning 120,340 shares worth approximately $2.08 million.
• Several institutional investors, including Vestal Point Capital LP and Ameriprise Financial Inc., have also raised their stakes in Structure Therapeutics, indicating strong interest from the investment community.
• Analysts have adjusted their price targets for Structure Therapeutics, with HC Wainwright lowering it from $75 to $60, while the average rating for the stock remains a "Buy" with a target price of approximately $75.71.

Trexquant Investment LP increased its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 127.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,340 shares of the company's stock after buying an additional 67,464 shares during the period. Trexquant Investment LP owned about 0.21% of Structure Therapeutics worth $2,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GPCR. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 5.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock valued at $112,816,000 after purchasing an additional 203,010 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after purchasing an additional 575,000 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Structure Therapeutics by 29.4% in the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after acquiring an additional 322,601 shares during the last quarter. Readystate Asset Management LP increased its stake in shares of Structure Therapeutics by 129.9% in the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock worth $8,330,000 after acquiring an additional 271,899 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Structure Therapeutics by 6.1% in the 1st quarter. Invesco Ltd. now owns 394,386 shares of the company's stock worth $6,827,000 after acquiring an additional 22,619 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on GPCR shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Lifesci Capital raised Structure Therapeutics to a "strong-buy" rating in a research report on Monday. JMP Securities cut their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. HC Wainwright lowered their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, Guggenheim decreased their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, Structure Therapeutics currently has an average rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Stock Down 1.7%

GPCR traded down $0.36 during trading on Wednesday, hitting $20.89. 563,280 shares of the stock were exchanged, compared to its average volume of 1,063,670. The firm has a market capitalization of $1.20 billion, a P/E ratio of -19.90 and a beta of -1.88. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $45.37. The stock has a fifty day moving average price of $18.89 and a two-hundred day moving average price of $20.68.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08). Analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.